Amber completed her PhD in immunology at the University of Birmingham in 2025, focusing on identifying new therapies, discovering novel biomarkers, and improving diagnostics for patients with autoimmune hepatitis. She previously earned a BSc in Biological Sciences from the University of Plymouth in 2019.
Alongside her PhD, Amber was working as a Research Technician at the University of Birmingham, where she lead single cell mass cytometry and scRNA-seq projects in collaboration with TransBioLine and GlaxoSmithKline. Her work involved advanced immunoprofiling techniques to better understand immune responses in liver disease.
Amber is passionate about translational immunology and bridging the gap between laboratory science and clinical application. She has collaborated with clinicians and industry partners to develop innovative approaches for improving patient outcomes.
As she continues her career in immunology, Amber aims to advance the understanding of immune dysregulation in liver disease and contribute to the development of novel therapeutic strategies.